Goodbye Lantus, Hello Optisulin: Sanofi to swap long-acting insulin brands

Clinicians have six months to transition their patients using Sanofi’s long-acting insulin glargine Lantus over to the company’s second brand Optisulin.  The pharmaceutical company has announced the recent PBS listing of Optisulin and at the same time foreshadowed the delisting of Lantus from 1 July 2020.  Given the two drugs have the same formulation, are ...

Already a member?

Login to keep reading.

© 2021 the limbic